<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04278651</url>
  </required_header>
  <id_info>
    <org_study_id>19G.929</org_study_id>
    <nct_id>NCT04278651</nct_id>
  </id_info>
  <brief_title>Early Antenatal Support for Iron Deficiency Anemia</brief_title>
  <acronym>EASI-A</acronym>
  <official_title>Early Antenatal Support for Iron Deficiency Anemia: A Randomized Controlled Trial of Early Initiation of Intravenous Versus Oral Iron Therapy for Treatment of Iron Deficiency Anemia in Pregnancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Auerbach Hematology and Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, controlled multi-site trial of iron therapy in pregnancy. The purpose
      of this research is to see if second trimester initiation of intravenous (IV) iron therapy is
      better than oral iron therapy for treatment of anemia in pregnancy by improving blood count,
      quality of life and reducing side effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pregnant singletons diagnosed with iron deficiency anemia will be enrolled between 14-24
      weeks and will be randomized 1:1 to either a course of ferumoxytol (510mg x 2 doses 3-8 days
      apart) or oral iron (325mg) twice daily.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Hemoglobin</measure>
    <time_frame>90 days</time_frame>
    <description>Change in hemoglboin at day 90 following treatment initiation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anemia resolution</measure>
    <time_frame>90 days</time_frame>
    <description>Percent of participants in each group with Hb&gt;=11.0 at day 90</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anemia at Delivery</measure>
    <time_frame>9 months</time_frame>
    <description>Percent of participants in each group with Hb&gt;=11.0 at delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for additional therapy</measure>
    <time_frame>9 months</time_frame>
    <description>Percent of participants in each group requiring additional therapy for iron deficiency anemia after 28 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life scale</measure>
    <time_frame>30, 60, 90 days</time_frame>
    <description>Linear Analogue Scale Assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence</measure>
    <time_frame>90 days</time_frame>
    <description>adherence to assigned group. Measured by what % of IV infusions completed of the two required in IV iron group, and for oral iron group, what %pills taken/prescribed based on pill counts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for post partum transfusion</measure>
    <time_frame>9 months</time_frame>
    <description>Incidence of transfusion after delivery/post partum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal outcomes: cord blood iron indices</measure>
    <time_frame>9 months</time_frame>
    <description>Hb, ferritin, total iron saturation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal outcomes: birth weight</measure>
    <time_frame>9 months</time_frame>
    <description>birth weight (grams)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal outcomes gestational age of delivery (weeks)</measure>
    <time_frame>9 months</time_frame>
    <description>gestational age of delivery (weeks)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Pregnancy Related</condition>
  <condition>Anemia, Iron Deficiency</condition>
  <condition>Anemia of Pregnancy</condition>
  <arm_group>
    <arm_group_label>Oral Iron</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>325mg oral iron (ferrous sulfate) twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous Iron</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>510mg ferumoxytol intravenous infusion for two doses total; second dose 3-8 days after first dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferumoxytol</intervention_name>
    <description>510mg infusion x 2 doses 3-8 days apart</description>
    <arm_group_label>Intravenous Iron</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferrous Sulfate</intervention_name>
    <description>325mg oral twice daily</description>
    <arm_group_label>Oral Iron</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Singleton gestation

          -  Gestational age &lt;24 weeks

          -  Baseline Hb â‰¥9.0 and &lt;11.0 with evidence of iron deficiency anemia

        Iron deficiency anemia diagnosed (at any point in patient history) by:

          -  Hb&lt;11.0

          -  Ferritin&lt;30 and/or total iron saturation &lt;20

        Exclusion Criteria:

          -  Sickle cell Disease (NOT sickle cell trait)

          -  Evidence of acute anemia requiring transfusion or IV iron therapy

          -  Major congenital or chromosomal anomaly

          -  Previous use of IV iron in this pregnancy

          -  Severe cardiac, renal, or liver disease

          -  Autoimmune disease (ie Systemic Lupus Erythematosus (SLE)

          -  Allergy or contraindication to either study drug

          -  History of medication allergy, reaction to IV infusion, or reaction to Feraheme or
             other IV iron products
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rupsa C Boelig, MD</last_name>
    <phone>215-955-9196</phone>
    <email>rupsa.boelig@jefferson.edu</email>
  </overall_contact>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>February 4, 2020</study_first_submitted>
  <study_first_submitted_qc>February 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2020</study_first_posted>
  <last_update_submitted>April 9, 2020</last_update_submitted>
  <last_update_submitted_qc>April 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ferrosoferric Oxide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After completion of planned primary and secondary analysis, IPD data may be available on request with completion of appropriate data sharing agreements</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>1 year after publication of study results</ipd_time_frame>
    <ipd_access_criteria>After completion of planned primary and secondary analysis, IPD data may be available on request with completion of appropriate data sharing agreements</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

